Zymeworks (ZYME) Competitors $18.73 +0.33 (+1.79%) As of 01:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. PTGX, TGTX, PTCT, KRYS, ARWR, ACLX, AKRO, CRNX, MENS, and NAMSShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors Protagonist Therapeutics TG Therapeutics PTC Therapeutics Krystal Biotech Arrowhead Pharmaceuticals Arcellx Akero Therapeutics Crinetics Pharmaceuticals Jyong Biotech NewAmsterdam Pharma Zymeworks (NASDAQ:ZYME) and Protagonist Therapeutics (NASDAQ:PTGX) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Do institutionals & insiders hold more shares of ZYME or PTGX? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to ZYME or PTGX? In the previous week, Protagonist Therapeutics had 1 more articles in the media than Zymeworks. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 10 mentions for Zymeworks. Protagonist Therapeutics' average media sentiment score of 0.74 beat Zymeworks' score of 0.44 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ZYME or PTGX? Protagonist Therapeutics has a consensus target price of $74.00, suggesting a potential downside of 4.63%. Given Protagonist Therapeutics' higher possible upside, analysts plainly believe Protagonist Therapeutics is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00Protagonist Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Is ZYME or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Zymeworks' net margin of -59.96%. Protagonist Therapeutics' return on equity of 8.12% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-59.96% -21.59% -16.52% Protagonist Therapeutics 24.88%8.12%7.41% Which has more risk and volatility, ZYME or PTGX? Zymeworks has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Which has better earnings and valuation, ZYME or PTGX? Protagonist Therapeutics has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$76.30M18.45-$122.69M-$0.97-19.31Protagonist Therapeutics$434.43M11.11$275.19M$0.70110.85 SummaryProtagonist Therapeutics beats Zymeworks on 14 of the 17 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$1.41B$1.04B$2.54B$10.69BDividend YieldN/A4.84%2.49%4.83%P/E Ratio-19.311.2921.9127.35Price / Sales18.4530.20114.18133.82Price / CashN/A17.6344.3430.35Price / Book3.818.1735.906.69Net Income-$122.69M-$7.36M$6.87M$276.36M7 Day Performance3.42%1.21%0.71%0.88%1 Month Performance15.26%30.33%0.53%3.83%1 Year PerformanceN/A-12.30%126.41%36.51% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks0.3477 of 5 stars$18.73+1.8%N/AN/A$1.41B$76.30M-19.31460Analyst DowngradePTGXProtagonist Therapeutics1.65 of 5 stars$87.00+29.8%$68.83-20.9%+65.0%$5.41B$209.18M124.29120Analyst ForecastHigh Trading VolumeTGTXTG Therapeutics4.4157 of 5 stars$33.76-3.5%$49.00+45.1%+48.7%$5.36B$454.07M91.24290Positive NewsPTCTPTC Therapeutics3.1939 of 5 stars$66.23+0.3%$69.00+4.2%+68.7%$5.26B$1.76B9.501,410News CoverageAnalyst ForecastAnalyst RevisionGap UpKRYSKrystal Biotech4.7737 of 5 stars$181.47-3.9%$209.00+15.2%+6.2%$5.25B$359.21M36.88210News CoverageAnalyst ForecastARWRArrowhead Pharmaceuticals3.702 of 5 stars$35.41-1.8%$43.14+21.8%+73.8%$4.90B$3.55M-27.66400Gap UpACLXArcellx2.4086 of 5 stars$86.80-1.8%$112.69+29.8%-10.2%$4.81B$107.94M-25.3880High Trading VolumeAKROAkero Therapeutics3.7529 of 5 stars$53.88-0.4%$73.38+36.2%+72.4%$4.31BN/A-26.9430High Trading VolumeCRNXCrinetics Pharmaceuticals4.4038 of 5 stars$44.93-1.8%$74.45+65.7%-29.6%$4.23B$1.39M-10.93210Positive NewsMENSJyong BiotechN/A$55.24+2.2%N/AN/A$4.20BN/A0.0031Gap DownHigh Trading VolumeNAMSNewAmsterdam Pharma2.7623 of 5 stars$37.05+12.2%$42.00+13.4%+89.0%$4.17B$45.56M-22.874Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Protagonist Therapeutics Alternatives TG Therapeutics Alternatives PTC Therapeutics Alternatives Krystal Biotech Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Akero Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Jyong Biotech Alternatives NewAmsterdam Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYME) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
